Abstract
Objective: To investigate the inhibitory effects and the mechanism of NF-κB decoy oligodeoxynucleotides (ODN) on Kupffer cells (KCs) activation.
Methods: KCs were isolated and randomly divided into three groups: (1) a control group; (2) an LPS stimu1ation group and (3) an NF-κB decoy group, in which the KCs were transduced with an NF-κB decoy ODN prior to LPS stimulation. Following 6 hours of LPS stimulation, the NF-κB activity was assayed by an electrophoretic mobility shift assay (EMSA). The CD80 mRNA expression in the KCs was detected by reverse transcription-polymerase chain reaction (RT-PCR), and the production of TNF-α and IL-6 in the supernatant was measured by an enzyme-linked immune sorbent assay (ELISA).
Results: The NF-κB decoy ODN could efficiently inhibit KCs activation by LPS stimulus. The NF-κB activity was significantly decreased to 0.53 fold as compared with the LPS group. The CD80 mRNA expression, TNF-α production, and IL-6 level were significantly decreased to 0.46, 0.37, and 0.60 fold, respectively.
Conclusion: The NF-κB decoy ODN could efficiently suppress transcription activity of NF-κB and inhibit co-stimulatory molecules and cytokines expression by KCs, which afford reliable experimental data for the in vivo application of NF-κB decoy ODN.
Keywords: Cytokines, Kupffer cells, LPS, NF-κB, oligodeoxynucleotides, TNF-α.
Current Signal Transduction Therapy
Title:NF-κB Decoy Oligodeoxynucleotides Inhibits Kupffer Cell Activation
Volume: 10 Issue: 1
Author(s): Chun Huang, Shan-mao Nie, Yi-ming Liu, Min Li, Jian-ping Gong and Meng-hao Wang
Affiliation:
Keywords: Cytokines, Kupffer cells, LPS, NF-κB, oligodeoxynucleotides, TNF-α.
Abstract: Objective: To investigate the inhibitory effects and the mechanism of NF-κB decoy oligodeoxynucleotides (ODN) on Kupffer cells (KCs) activation.
Methods: KCs were isolated and randomly divided into three groups: (1) a control group; (2) an LPS stimu1ation group and (3) an NF-κB decoy group, in which the KCs were transduced with an NF-κB decoy ODN prior to LPS stimulation. Following 6 hours of LPS stimulation, the NF-κB activity was assayed by an electrophoretic mobility shift assay (EMSA). The CD80 mRNA expression in the KCs was detected by reverse transcription-polymerase chain reaction (RT-PCR), and the production of TNF-α and IL-6 in the supernatant was measured by an enzyme-linked immune sorbent assay (ELISA).
Results: The NF-κB decoy ODN could efficiently inhibit KCs activation by LPS stimulus. The NF-κB activity was significantly decreased to 0.53 fold as compared with the LPS group. The CD80 mRNA expression, TNF-α production, and IL-6 level were significantly decreased to 0.46, 0.37, and 0.60 fold, respectively.
Conclusion: The NF-κB decoy ODN could efficiently suppress transcription activity of NF-κB and inhibit co-stimulatory molecules and cytokines expression by KCs, which afford reliable experimental data for the in vivo application of NF-κB decoy ODN.
Export Options
About this article
Cite this article as:
Huang Chun, Nie Shan-mao, Liu Yi-ming, Li Min, Gong Jian-ping and Wang Meng-hao, NF-κB Decoy Oligodeoxynucleotides Inhibits Kupffer Cell Activation, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1573407211666150603201802
DOI https://dx.doi.org/10.2174/1573407211666150603201802 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycine/NMDA Receptor Antagonists as Potential CNS Therapeutic Agents: ACEA-1021 and Related Compounds
Current Topics in Medicinal Chemistry Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) HIF-1α as a Target for Drug Design in Ischemic Injury: Effect of Cobalt Treatment on Mitochondrial DNA Damage in Cells Exposed to H2O2
Letters in Drug Design & Discovery The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Heme Oxygenase in Regulation of Renal Function and Blood Pressure
Current Hypertension Reviews Mild Systemic Inflammation has a Neuroprotective Effect After Stroke in Rats
Current Neurovascular Research Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Current Topics in Medicinal Chemistry Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry Radiofluorinated Carbohydrates for Positron Emission Tomography
Current Topics in Medicinal Chemistry Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia
Current Neuropharmacology Exercise-Induced Overexpression of Angiogenic Factors and Reduction of Ischemia / Reperfusion Injury in Stroke
Current Neurovascular Research Phytochemical and Biological Activities of five Turanecio Hamzaoglu (Asteraceae) Species from Turkey
Current Enzyme Inhibition Mn-SOD and Chronic Inflammation of Gastric Mucosa
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Small Molecule Antagonists of the CXCR2 and CXCR1 Chemokine Receptors as Therapeutic Agents for the Treatment of Inflammatory Diseases
Current Topics in Medicinal Chemistry Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design